by Richard Daverman, PhD
November 27, 2013 -- ShangPharma, one of China’s largest CROs, signed an exclusive China license agreement with Mabspace International to specific Mabspace antigens and technology for CRO use in antibody discovery. Founded in 2011, Mabspace discovers novel fast follow-on antibody-based therapeutic agents that target chronic kidney diseases, cancer and autoimmune disorders. Mabspace is headquartered in Hong Kong with a mainland subsidiary in Suzhou BioBay. More details....
Help employers find you! Check out all the jobs and post your resume.
